Oncogenic osteomalacia illustrating the effects of fibroblast factor 23 on phospahte homeostasis
2012 (English)In: Clinical Kidney Journal, ISSN 2048-8505, Vol. 5, no 3, 240-243 p.Article in journal (Refereed) Published
In oncogenic osteomalacia (OOM), fibroblast growth factor 23 (FGF23) induces renal phosphate wasting and inhibits the appropriate increase of calcitriol. A patient suffering from OOM is described. Serum calcium, phosphate, biointact parathyroid hormone and intact FGF23 as well as the calcitriol and 24,25-vitamin D levels were measured before and after tumour removal. The clinical approach to a patient with hypophosphataemia is discussed and the changes in mineral metabolism after removal of a FGF23-producing tumour are described.
Place, publisher, year, edition, pages
2012. Vol. 5, no 3, 240-243 p.
Urology and Nephrology
IdentifiersURN: urn:nbn:se:uu:diva-188144DOI: 10.1093/ckj/sfs031OAI: oai:DiVA.org:uu-188144DiVA: diva2:576365
Clinical report2012-12-122012-12-122013-02-21Bibliographically approved